:: portfolio news :: Xanthus Xanthus Gets SPA Clearance For Trials In Secondary AML >> US Genomics: U.S. Genomics Recognized for Outstanding Entrepreneurship by the National Science Foundation (NSF) >> Xanthus Xanthus' Symadex Can Reverse Disease in Preclinical MS Animal >> US Genomics: Growing pains at U.S. Genomics >> Stargus C-COR announces agreement on terms to purchase Stargus >> Bus-Tech The importance of being flexible: Bus-Tech adapts >> MEMSIC Leaders from fourteen companies named New England Entrepreneur of the Year Award >>

		About Us | Portfolio | Team | Contact Us	© 2004 Still River Funds. All Rights Reserved.